| 1. |
Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin, 2013, 63(1): 11-30.
|
| 2. |
Chen W, Sun K, Zheng R, et al. Cancer incidence and mortality in China, 2014. Chin J Cancer Res, 2018, 30(1): 1-12.
|
| 3. |
Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet, 2018, 391(10125): 1023-1075.
|
| 4. |
张太平, 曹喆, 赵玉沛. 多学科诊疗模式在胰腺癌综合诊治决策中的价值. 中国普外基础与临床杂志, 2017, 24(6): 665-667.
|
| 5. |
Katz MH, Kim MP, Tzeng CW, et al. Preoperative chemoradiation for borderline resectable pancreatic cancer: the new standard? Ann Surg, 2018, [Epub ahead of print].
|
| 6. |
梁廷波, 白雪莉, 李想. 胰腺癌新辅助治疗的进展及面临的问题. 中国普外基础与临床杂志, 2017, 24(6): 657-660.
|
| 7. |
Asada S, Itaya H, Nakamura K, et al. Radical pancreatoduodenectomy and portal vein resection. Report of two successful cases with transplantation of portal vein. Arch Surg, 1963, 87: 609-613.
|
| 8. |
Allema JH, Reinders ME, van Gulik TM, et al. Portal vein resection in patients undergoing pancreatoduodenectomy for carcinoma of the pancreatic head. Br J Surg, 1994, 81(11): 1642-1646.
|
| 9. |
Fuhrman GM, Leach SD, Staley CA, et al. Rationale for en bloc vein resection in the treatment of pancreatic adenocarcinoma adherent to the superior mesenteric-portal vein confluence. Pancreatic Tumor Study Group. Ann Surg, 1996, 223(2): 154-162.
|
| 10. |
Leach SD, Lee JE, Charnsangavej C, et al. Survival following pancreaticoduodenectomy with resection of the superior mesenteric-portal vein confluence for adenocarcinoma of the pancreatic head. Br J Surg, 1998, 85(5): 611-617.
|
| 11. |
Tseng JF, Raut CP, Lee JE, et al. Pancreaticoduodenectomy with vascular resection: margin status and survival duration. J Gastrointest Surg, 2004, 8(8): 935-949.
|
| 12. |
Kitagawa H, Ohta T, Tajima H, et al. En bloc resection including the superior mesenteric artery and vein of locally advanced pancreatic carcinomas. Nihon Geka Gakkai Zasshi, 2011, 112(3): 164-169.
|
| 13. |
Esposito I, Kleeff J, Bergmann F, et al. Most pancreatic cancer resections are R1 resections. Ann Surg Oncol, 2008, 15(6): 1651-1660.
|
| 14. |
Varadhachary GR, Tamm EP, Crane C, et al. Borderline resectable pancreatic cancer. Curr Treat Options Gastroenterol, 2005, 8(5): 377-384.
|
| 15. |
Varadhachary GR, Tamm EP, Abbruzzese JL, et al. Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol, 2006, 13(8): 1035-1046.
|
| 16. |
Lopez NE, Prendergast C, Lowy AM. Borderline resectable pancreatic cancer: definitions and management. World J Gastroenterol, 2014, 20(31): 10740-10751.
|
| 17. |
Tempero MA, Malafa MP, Al-Hawary M, et al. Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 2017, 15(8): 1028-1061.
|
| 18. |
中国抗癌协会胰腺癌专委会. 胰腺癌综合诊治指南 (2018 版). 2018-04. http://guide.medlive.cn/guideline/15566..
|
| 19. |
Katz MH, Pisters PW, Evans DB, et al. Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg, 2008, 206(5): 833-846.
|
| 20. |
Isaji S, Mizuno S, Windsor JA, et al. International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017. Pancreatology, 2018, 18(1): 2-11.
|
| 21. |
Hayasaki A, Isaji S, Kishiwada M, et al. Survival Analysis in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Chemoradiotherapy Followed by Surgery According to the International Consensus on the 2017 Definition of Borderline Resectable Cancer. Cancers (Basel), 2018, 10(3): E65.
|
| 22. |
Liu L, Xu H, Wang W, et al. A preoperative serum signature of CEA+/CA125+/CA19-9≥1 000 U/mL indicates poor outcome to pancreatectomy for pancreatic cancer. Int J Cancer, 2015, 136(9): 2216-2227.
|
1/5
WeChat